Upgrades:
United Parcel Service (NYSE:UPS) was upgraded by equities
research analysts at Daiwa Capital Markets from a “neutral” rating to an
“outperform” rating in a report released on Monday, The Fly reports. A number
of other equities analysts also recently commented on UPS. Argus restated a
“buy” rating on shares of United Parcel Service in a research note on Tuesday,
April 30th. Credit Suisse Group set a $119.00 price objective on shares of
United Parcel Service and gave the stock a “neutral” rating in a research note
on Wednesday, July 31st. UBS Group increased their price objective on shares of
United Parcel Service to $128.00 and gave the stock a “buy” rating in a
research note on Thursday, July 25th. Goldman Sachs Group initiated coverage on
shares of United Parcel Service in a research note on Wednesday, July 10th.
They set a “buy” rating and a $123.00 price objective for the company. Finally,
Stifel Nicolaus cut shares of United Parcel Service from a “buy” rating to a
“hold” rating and set a $118.00 target price on the stock. in a report on
Monday, July 29th. One analyst has rated the stock with a sell rating, eleven
have given a hold rating, eight have given a buy rating and one has issued a
strong buy rating to the stock. The stock has a consensus rating of “Hold” and
a consensus price target of $118.82. Read more …
Oppenheimer upgraded shares of Verizon Communications (NYSE:VZ)
from a market perform rating to an outperform rating in a research report
released on Tuesday, The Fly reports. The brokerage currently has $70.00 price
objective on the cell phone carrier’s stock. VZ has been the topic of a number
of other research reports. Citigroup lowered Verizon Communications from a buy
rating to a neutral rating and set a $62.00 price objective on the stock. in a
report on Monday, July 8th. Zacks Investment Research raised Verizon
Communications from a hold rating to a buy rating and set a $58.00 price
objective on the stock in a report on Monday, August 5th. Finally, UBS Group
lowered Verizon Communications from a buy rating to a neutral rating and set a
$57.70 price objective on the stock. in a report on Thursday, May 30th. They
noted that the move was a valuation call. Nine research analysts have rated the
stock with a hold rating and five have issued a buy rating to the stock. The
company presently has an average rating of Hold and an average price target of
$60.22. Read more …
DZ Bank upgraded shares of Pfizer (NYSE:PFE) from a sell
rating to a hold rating in a report issued on Wednesday morning, The Fly
reports. They currently have $36.00 price objective on the biopharmaceutical
company’s stock. PFE has been the topic of a number of other research reports.
JPMorgan Chase & Co. set a $46.00 price target on shares of Pfizer and gave
the stock a neutral rating in a report on Monday, July 29th. Bank of America
cut shares of Pfizer from a buy rating to a neutral rating in a report on
Tuesday, July 30th. Morgan Stanley lowered their price target on shares of
Pfizer from $40.00 to $38.00 and set an equal weight rating on the stock in a
report on Tuesday. UBS Group reaffirmed a neutral rating and issued a $43.00
price target on shares of Pfizer in a report on Monday, August 5th. Finally,
Barclays reaffirmed a hold rating and issued a $41.00 price target on shares of
Pfizer in a report on Thursday, May 9th. Fifteen investment analysts have rated
the stock with a hold rating and four have given a buy rating to the company’s
stock. The company has an average rating of Hold and a consensus price target
of $45.88. Read more …
Novo Nordisk A/S (NYSE:NVO) was upgraded by research
analysts at Pareto Securities from a “hold” rating to a “buy” rating in a
research report issued to clients and investors on Monday, August 5th, The Fly
reports. A number of other analysts also recently issued reports on NVO. Deutsche
Bank downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold”
rating and set a $52.42 price objective for the company. in a report on
Thursday, June 20th. UBS Group reiterated a “buy” rating and set a $355.00
target price on shares of Novo Nordisk A/S in a research report on Wednesday,
June 19th. Zacks Investment Research upgraded shares of Novo Nordisk A/S from a
“sell” rating to a “hold” rating and set a $50.00 target price for the company
in a research report on Monday, July 15th. Barclays raised shares of Novo
Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a
$51.85 target price on the stock in a research note on Tuesday, June 11th.
Finally, Credit Suisse Group upgraded shares of Novo Nordisk A/S from a “neutral”
rating to an “outperform” rating in a research note on Monday, April 29th. One
analyst has rated the stock with a sell rating, ten have given a hold rating
and six have given a buy rating to the company’s stock. The stock has an
average rating of “Hold” and a consensus target price of $111.58. Read more …
Downgrades:
Foot Locker (NYSE:FL) was downgraded by analysts at Robert
W. Baird from an “outperform” rating to a “neutral” rating in a note issued to
investors on Monday, Briefing.com Automated Import reports. They currently have
a $37.00 target price on the athletic footwear retailer’s stock, down from
their prior target price of $54.00. Robert W. Baird’s price target points to a
potential upside of 8.82% from the company’s current price. Other equities
analysts also recently issued research reports about the stock. Canaccord
Genuity cut their price target on shares of Foot Locker from $82.00 to $81.00
and set a “buy” rating on the stock in a research note on Friday, May 24th.
Guggenheim reaffirmed a “buy” rating and set a $60.00 price target on shares of
Foot Locker in a research note on Friday, May 24th. ValuEngine downgraded
shares of Foot Locker from a “hold” rating to a “sell” rating in a research
note on Friday, May 24th. Deutsche Bank cut their target price on shares of
Foot Locker from $68.00 to $63.00 and set a “buy” rating on the stock in a
research note on Monday, August 19th. Finally, Pivotal Research reissued a
“buy” rating and issued a $53.00 target price on shares of Foot Locker in a
research note on Tuesday, August 20th. One investment analyst has rated the
stock with a sell rating, six have issued a hold rating and thirteen have given
a buy rating to the company’s stock. The company has a consensus rating of
“Buy” and a consensus price target of $62.89. Read more …
Barclays downgraded shares of Anheuser Busch Inbev
(NYSE:BUD) from an equal weight rating to an underweight rating in a report
released on Tuesday, BenzingaRatingsTable reports. Several other research
analysts have also recently issued reports on the company. Bank of America
upgraded Anheuser Busch Inbev from a neutral rating to a buy rating in a
research report on Monday, July 29th. They noted that the move was a valuation
call. Argus upgraded Anheuser Busch Inbev from a hold rating to a buy rating in
a research report on Thursday, May 30th. UBS Group cut Anheuser Busch Inbev
from a buy rating to a neutral rating in a research report on Tuesday, August
6th. ValuEngine upgraded Anheuser Busch Inbev from a sell rating to a hold
rating in a research report on Friday, July 19th. Finally, Jefferies Financial
Group upgraded Anheuser Busch Inbev to a hold rating and set a $95.00 price
target for the company in a research report on Monday, August 12th. One analyst
has rated the stock with a sell rating, eight have issued a hold rating and
three have issued a buy rating to the stock. Anheuser Busch Inbev presently has
an average rating of Hold and a consensus target price of $89.27. Read more …
Cardinal Health (NYSE:CAH) was downgraded by stock analysts
at Argus from a “buy” rating to a “hold” rating in a note issued to investors
on Tuesday, The Fly reports. Several other brokerages have also commented on
CAH. Guggenheim raised Cardinal Health from a “neutral” rating to a “buy”
rating and boosted their price target for the stock from $50.00 to $52.00 in a
research note on Tuesday, August 20th. ValuEngine raised Cardinal Health from a
“strong sell” rating to a “sell” rating in a research note on Thursday, May
9th. Three investment analysts have rated the stock with a sell rating, six have
issued a hold rating and one has assigned a buy rating to the company’s stock.
The company has an average rating of “Hold” and a consensus target price of
$55.00. Read more …
Comments
Post a Comment